Published 5 hours ago • loading... • Updated 5 hours ago

Elevar Therapeutics Announces First Patients Dosed in Phase 2 Study of Lirafugratinib Among Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement

First patient was dosed at Samsung Medical Center in Seoul, South Korea; a second at Moffitt Cancer Center in Tampa,

First patient was dosed at Samsung Medical Center in Seoul, South Korea; a second at Moffitt Cancer Center in Tampa,

5 hours ago

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Total News Sources1

Leaning Left0Leaning Right0Center1Last Updated4 hours agoBias Distribution

100% Center

100% Center

To view factuality data please Upgrade to Premium

To view ownership data please Upgrade to Vantage

The Norfolk Daily News broke the news 5 hours ago on Monday, June 22, 2026.

Sources are mostly out of (0)